Search

everythinglearnresearchcommunity

for

Search:↓

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

A user shared their positive experience with hair regrowth after 3 months of using 6% Minoxidil and 0.3% Finasteride spray. They experienced temporary erectile dysfunction but it resolved, although morning erections are less frequent.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user has been using a combination of finasteride and minoxidil for three months and is seeing progress in hair regrowth. Other users encourage them to continue the treatment for further improvement.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

User wants to buy TO hair serum with redensyl but found a website not listing redensyl in ingredients. No specific treatments mentioned.

The user shared their 3-month hair loss progress using 1mg finasteride daily, minoxidil (liquid and foam), micro-needling, and keto shampoo. They reported positive results, with the crown area showing improvement.

The conversation is about a person showing significant hair regrowth after three months using finasteride and minoxidil. Some people congratulated the person, while others asked if they used derma rolling or oral minoxidil, to which they replied they used topical minoxidil.

The user shared progress pictures after using minoxidil and finasteride for three months, reporting hair stabilization and thickening. They used Amazon's brand for minoxidil and Good Rx for finasteride.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

The user has been using Nizoral shampoo, MCT oil with lavender oil, and tea tree conditioner for hair care, considering finasteride if no progress is seen. Some users notice progress in hair thickness and density after three months.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

The user shared impressive three-month progress using topical Minoxidil and Finasteride, along with derma rolling and collagen supplements. They reported no side effects and detailed their routine, including specific concentrations of the treatments used.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

A personalized topical anti-hair loss serum could include high-dose setipiprant, high-dose CB 03-01, low-dose finasteride, minoxidil, latanoprost, and tretinoin. These ingredients are suggested for their potential effectiveness in promoting hair growth.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Significant hair regrowth and thickening were achieved in three months using topical finasteride 0.3% and minoxidil 7%, along with lifestyle changes like healthier eating, derma stamping, and rosemary oil. Additional treatments included a shampoo for thinning hair and supplements like biotin and vitamin D.

A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.